Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcomeKatia Rea(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonella Tomassetti(University of Milan)OncotargetSeptember 4, 201510.18632/oncotarget.5087Cited by 35SaveCiteExport RISWatch citationsRelated PapersLigand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer|Oncogene|2011|116EGFR/MEK/ERK/CDK5-dependent integrin-independent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor cells|Cell Death and Disease|2013|41